Suven Life Sciences Limited
Suven Life Sciences Limited operates in Healthcare Research, Analytics & Technology, part of the Healthcare sector. It booked ₹4 cr of revenue in its latest quarter (Q1 FY27). It is the 3rd largest of 5 Healthcare Research, Analytics & Technology companies we track, by market value.
From the company's consolidated segment filings (Ind AS 108). Margin is segment operating profit (before interest & tax) over segment revenue; reconciliation rows like inter-segment eliminations are excluded from the mix.
“Founded in Hyderabad by Mr Venkateswarlu Jasti, In recent times, Suven faced financial strain from high FINANCIAL PERFORMANCE Chairman & MD, more than three decades ago, R&D costs but gained traction with promising phase Suven Life Sciences is a biopharmaceutical company II results for a depression drug, boosting its stock. Suven Life Sciences stands out due to its operating model, where R&D expenses exceed revenue.”
Healthier than 25% of companies in Healthcare, on all six measures of filed financials. Each measure is ranked against the 105–150 companies that reported it.
Measures financial condition, not whether to buy. Learn what this score means · How this is calculated
- RSI (14)
- 47
At close. Not part of the score.
How much profit it earns on the money it employs · lowest in its sector on what we could measure
How much it owes, and whether earnings cover the interest
Whether reported profit actually arrives as cash · lowest in its sector on what we could measure
Whether sales and profit have grown, and how steadily
What today's price implies, against our models or its peers
How much of the promoters' stake is pledged, and how much they hold · highest in its sector on what we could measure
What if I invest in SUVEN?
Set a growth rate and see what a monthly SIP would add up to. Your assumption, our arithmetic.
The starting rate is a round number, not a view on this company — this is your assumption, and the figure above is arithmetic on it. Returns are not steady year to year, and a real holding would not grow in a straight line. We do not publish price targets or predict returns.
P/E, ROE, ROCE and margins are annualised from the latest quarter; per-share and balance-sheet ratios use the most recent balance sheet on file · prices as of 2026-09-17.
An educational model from the company's own filings, every assumption shown — not investment advice or a price target. Prices can stay above or below any model for years.
| Revenue from Operations | ₹4 cr |
| Other Income | ₹8 cr |
| Total Income | ₹11 cr |
| Cost of Materials | ₹0 cr |
| Purchases of Stock-in-Trade | ₹0 cr |
| Employee Benefit Expense | ₹7 cr |
| Finance Costs | ₹47.6 L |
| Depreciation & Amortisation | ₹2 cr |
| Other Expenses | ₹129 cr |
| Total Expenses | ₹139 cr |
| Profit before Tax | ₹-128 cr |
| Tax Expense | ₹0 cr |
| Net Profit | ₹-128 cr |
The company made a net loss of ₹128 cr this quarter — income covered only ₹8 of every ₹100 it spent on costs and tax.
| Metric | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|
| Revenue | 3 cr | 2 cr | 4 cr |
| Total income | 6 cr | 8 cr | 11 cr |
| Expenses | 108 cr | 54 cr | 139 cr |
| Profit before tax | -102 cr | -46 cr | -128 cr |
| Tax | 0 cr | 0 cr | 0 cr |
| Net profit (owners' share) | -102 cr | -46 cr | -128 cr |
| Net margin (owners' share, on revenue) | — | — | — |
| EPS (₹) | -4.55 | -2.02 | -4.84 |
| Company | Price | Market cap | P/E | ROE | Net margin | 1-yr return |
|---|---|---|---|---|---|---|
| Syngene International Limited | ₹380 | ₹15,349 cr | — | -0.7% | -1.2% | — |
| Indegene Limited | ₹592 | ₹14,232 cr | 30.6 | 14.8% | 10.9% | — |
| Suven Life Sciences Limitedthis company | ₹350 | ₹9,236 cr | — | -86.3% | — | — |
| Vimta Labs Limited | ₹600 | ₹1,332 cr | 19.1 | 25.1% | 23.9% | — |
| TAKE Limited | ₹17 | ₹248 cr | 60.0 | 13.7% | 3.5% | — |
| Action | Detail | Ex-date |
|---|---|---|
| Rights issue | 2:1 | 17 Oct 2022 |
| Dividend | ₹1.5 / share | 14 Feb 2019 |
| Dividend | ₹1.5 / share | 6 Feb 2018 |
| Dividend | ₹1 / share | 8 Feb 2017 |
| Dividend | ₹1 / share | 14 Mar 2016 |
| Dividend | ₹0.6 / share | 23 Jul 2015 |
A company cannot decide everything on its own. Things like a top executive’s pay, issuing new shares, or re-appointing a director have to be put to the people who own the company, and they vote — one vote per share. So whoever owns the most shares has the most say.
Every vote count above is taken from the result the company filed with the stock exchange, certified by an independent counter. To work out what would have happened without the promoters, we simply remove their votes and re-apply the same legal bar the proposal had to clear. Nothing here is an estimate or an opinion.
Most Indian companies are controlled by a family or group — the promoters. The exchange requires them to be listed by name, including members who own no shares at all, and requires the company to disclose any business it does with them.
Names and holdings from the company’s shareholding pattern filed with the exchange; transactions from the related-party note in its annual report. Every figure is as filed — these are legal, disclosed dealings, and what to make of them is your call.
When a company raises money from investors, it has to say up front what the money is for. The rules then make it report, every three months until the money is gone, how much of each of those things it has actually paid for — so a promise made while asking for the money can be checked afterwards.
As of Jun 2026, the company says it has spent 48% of what it set aside, leaving ₹448 cr still to be spent. CRISIL Ratings Limited watches the spending on the exchange’s behalf.
As of Mar 2025, the company says it has spent 100% of what it set aside. CRISIL Ratings Limited watches the spending on the exchange’s behalf.
Every figure above is taken from the statement the company files with the stock exchange each quarter, for as long as money it has raised remains unspent. The only thing we work out is how much of each stated purpose has been paid for — one number divided by another from the same filing. Whether a plan that changed was a good change is not something a filing can tell you. See the filing